Biovica and the outlook after the CMD: A road map to the US market

Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Biovica and the outlook after the CMD: A road map to the US market

2022-05-19

08:55

JU

Johan Unnerus

Biovica’s CLIA certified San Diego lab, together with the summer of 2022 FDA 510 (k) approval is the backbone of Biovica’s strategy to reach most of the US market.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Biovica International

36.9

▼ 1.6

-4.16%

Premium Plan required to unlock

Biovica International

36.9

▼ 1.6

-4.16%

Premium Plan required to unlock